Home > Oncology > ESMO 2020 > Breast Cancer > Second-line sacituzumab govitecan improves survival in metastatic TNBC

Second-line sacituzumab govitecan improves survival in metastatic TNBC

ESMO 2020
In pretreated metastatic TNBC patients, standard of care chemotherapy is associated with low objective response rates (ORRs) and short median progression-free survival (PFS). Results of the phase 3 ASCENT trial show improved ORR rates, and improved survival. Sacituzumab govitecan is an antibody-drug conjugate composed of an anti-Trop-2 antibody coupled to SN-38, the active metabolite of irinotecan. Trop-2 is expressed in all subtypes of breast cancer and linked to a poor prognoses. SN-38 is released both intracellularly and in the tumour microenvironment. Based on the results of a phase 1/2 trial, the FDA recently approved sacituzumab govitecan for treatment of refractory, metastatic TNBC [1]. In the phase 3 ASCENT study, 468 metastatic TNBC patients who had relapsed or had refractory disease after ≥2 prior chemotherapies in the advanced/metastatic setting were randomised 1:1 to sacituzumab govitecan (10 mg/kg IV on day 1 and 8, every 3 weeks) or s...

Please login to read the full text of the article.

If you have no account yet, please register now.

Posted on